Financial Data and Key Metrics Changes - Total revenue for Q4 2025 grew 12% to a record $6.6 million, with full-year revenue increasing 13% to $22.7 million, marking another company record [6][23] - Gross margin for Q4 2025 increased to 91.4% from 91.1% in Q4 2024, reflecting the strength of the software-driven SaaS model [6][25] - The company achieved annual operating profitability for the first time since going public, with net income of $1.3 million and EPS of $0.06 for the year [7][23] - Adjusted EBITDA for Q4 2025 was a record $1.9 million, with full-year adjusted EBITDA reaching $2.6 million, nearly five times the previous year [7][23] Business Line Data and Key Metrics Changes - SaaS revenue for Q4 2025 grew 12% to $6.62 million, representing over 99% of total revenue for the quarter [25] - The average price per transaction increased by 25% in Q4 2025 compared to the previous year, indicating pricing power for the company's unique product [18] Market Data and Key Metrics Changes - The banking and lending sector showed significant growth, with year-over-year revenue growth nearly doubling, while retail was down 1% year-over-year [39] - The automotive sector experienced a 125% year-over-year revenue growth, with significant opportunities for expansion through channel partners [71] Company Strategy and Development Direction - The company aims to build a durable, differentiated, high-margin business by expanding with existing customers and onboarding new ones while maintaining disciplined execution [21] - Continued investment in customer success and deepening presence in key verticals, particularly financial services and banking, is a strategic priority [37] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in various verticals, particularly in banking and automotive, despite current economic challenges [17][18] - The company is well-positioned to benefit from a potential decrease in interest rates, which could act as a tailwind for growth [54] Other Important Information - The company has a strong cash position, ending the year with $9.6 million in cash and cash equivalents, reflecting strong cash generation from operations [35] - The decline in software capitalization from over $2 million in 2024 to just $213,000 in 2025 indicates a cleaner financial profile moving forward [36] Q&A Session Summary Question: What was the revenue breakdown for the banking and retail channels in Q4? - Management noted that banking and lending revenue continues to grow significantly, while retail saw a seasonal increase but was down year-over-year [39][41] Question: How does the pipeline look for new customers in 2026? - The pipeline appears strong, driven by interest in the new desktop solution and partnerships, particularly with Alloy [42][43] Question: What is the status of the relationship with Ping Identity? - Management acknowledged the need for improvement in leveraging the partnership with Ping Identity to facilitate growth [47] Question: Can you provide growth expectations for 2026? - While the company does not provide formal guidance, management expressed confidence in built-in growth from existing clients and new implementations [63] Question: What metrics can be shared regarding the automotive sector? - Automotive revenue grew 125% year-over-year, with significant opportunities for further penetration through channel partners [71]

Financial Data and Key Metrics Changes - For fiscal 2025, the company achieved net sales of $1 billion and adjusted EBITDA of $63.6 million, reaching the top end of its guidance [4][22] - In Q4, net sales were $236.2 million, down from $275.6 million in the prior year, with a comparable sales decline of 10% [23] - Gross profit for Q4 was $70.9 million, with a gross margin of 30%, compared to 33.6% in the prior year [23] - SG&A expenses decreased by $11.4 million to $62.4 million, representing 26.4% of net sales [23][24] - The net loss for Q4 was $8.1 million, or $0.08 per share, compared to a net loss of $3 million, or $0.03 per share, in the previous year [24] Business Line Data and Key Metrics Changes - The company saw strength in dresses, with growth for four consecutive quarters, and a turnaround in knit tops in the latter half of Q4 [6][7] - Sub-brands generated over $70 million in sales in 2025, with projected growth of approximately 60% in 2026 to around $110 million [11] - The footwear category was successfully reintroduced, with sold-out limited assortments, and is expected to contribute positively in the back half of 2026 [7][15] Market Data and Key Metrics Changes - The company closed 151 stores in fiscal 2025, with an additional 11 closures in Q1 2026, optimizing its store footprint [8][25] - Customer retention rates from closed locations have performed consistently with historical levels, validating the network strategy [25][26] - The company entered 2026 with a balanced inventory position of $136.5 million, down 8% [25] Company Strategy and Development Direction - The primary focus for 2026 is accelerating customer file growth through retention, reactivation, and acquisition [4][7] - The company aims to optimize its channel, product, and pricing platforms, with a disciplined approach to product development [20][19] - The opening price point strategy now represents approximately 30% of total assortment and is expected to grow to nearly 40% [16][20] Management Comments on Operating Environment and Future Outlook - Management acknowledged economic pressures affecting customer spending and emphasized the importance of accessible pricing [36][51] - The company expects to face headwinds in the first half of 2026 but anticipates a positive impact in the second half, particularly from the footwear category [15][47] - The outlook for fiscal 2026 includes expected net sales of $940 million to $960 million and adjusted EBIT of $65 million to $75 million [27] Other Important Information - The company has completed a substantial two-year transformation, optimizing its channel, product, and pricing platforms [20] - The marketing investment decreased by $1.9 million to $13.5 million, reflecting a more disciplined approach [24] - The company has over 7 million lapsed customers reachable through owned marketing channels, presenting a significant opportunity for reactivation [19][20] Q&A Session Summary Question: Insights on sub-brands performance and growth expectations - Management expressed satisfaction with sub-brands, highlighting strong performers and adjusting growth expectations to mid-teens for 2026 [31][32] Question: Reasons for customer lapses and reactivation strategies - Management noted economic pressures as a primary reason for lapses and emphasized targeted segmentation and personalized messaging for reactivation [36][37] Question: Sales cadence during the holiday season and tariff impacts - Management reported improvement in January sales and acknowledged tariff pressures affecting margins, particularly in footwear [42][44] Question: Marketing plans for pricing and loyalty program changes - Management discussed a shift towards less reliance on Torrid Cash and more focus on opening price points and targeted promotions to drive frequency [50][51] Question: Future pricing and promotional strategies - Management indicated a more personalized approach to promotions and pricing, leveraging opening price points and sub-brands to engage customers [67][68] Question: Consumer behavior changes and expectations regarding refunds - Management observed consistent consumer behavior but noted economic pressures influencing spending; no outsized expectations related to tax refunds were embedded in guidance [75][77]

Financial Data and Key Metrics Changes - Relmada closed 2025 with a cash balance of $93 million, an increase from approximately $45 million at December 31, 2024, due to net proceeds from a $160 million private financing [19][20] - Research and development expenses for Q4 2025 totaled $8.1 million, a decrease from $11 million in Q4 2024, primarily due to reduced study costs [21] - General and administrative expenses increased to $12.3 million in Q4 2025 from $8.1 million in Q4 2024, driven by higher compensation costs [22] - The net loss for Q4 2025 was $19.9 million, or $0.27 per share, compared to a net loss of $18.7 million, or $0.62 per share, in Q4 2024 [23] Business Line Data and Key Metrics Changes - The NDV-01 program reported a 12-month complete response rate of 76% in high-risk NMIBC patients, with an 80% response rate in the BCG unresponsive population [11][12] - The planned phase III RESCUE program will evaluate NDV-01 in both second-line BCG unresponsive disease and as adjuvant therapy for intermediate-risk bladder cancer [14][15] Market Data and Key Metrics Changes - The U.S. market for intermediate-risk bladder cancer is estimated to have about 75,000-80,000 patients, with only 35% currently receiving adjuvant therapy [53] - The second-line treatment population for BCG unresponsive patients is estimated at about 5,000 patients per year in the U.S. [15] Company Strategy and Development Direction - The company aims to initiate the phase III RESCUE program for NDV-01 in mid-2026, focusing on two independent registrational pathways [6][14] - The strategy includes addressing unmet needs in bladder cancer treatment with a unique sustained-release formulation [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical programs and long-term prospects for Relmada, highlighting the importance of execution in the upcoming RESCUE program [24] - The company anticipates 2026 to be another significant year for value creation, with the initiation of key clinical trials [8] Other Important Information - The company has strengthened its development team with the appointment of Dr. Raj S. Pruthi as Chief Medical Officer-Oncology [7] - A successful $160 million private financing was completed, providing capital through 2029 [8] Q&A Session Summary Question: Will additional data from the phase II study be presented? - Management confirmed that updated 12-month data will be presented at the AUA and plans to share data every three months as the RESCUE trial progresses [29][30] Question: How will the company ensure that second-line patients are accurately categorized? - The company will limit prior therapy lines to two and will monitor patient characteristics closely to ensure accurate categorization [31] Question: What is the expected enrollment cadence across the studies? - Management indicated that the unique in-office profile of NDV-01 could serve as a recruitment advantage, and they expect rapid enrollment [34] Question: What is the FDA's requirement for follow-up duration prior to submitting the NDA? - The FDA has not stipulated a minimum follow-up duration but is interested in the totality of the data, including response and durability [36] Question: How does the company expect to compare against competitors in terms of CR rates? - Management indicated that they are targeting a two-year RFS of 75% and believe they can exceed this based on their data [42] Question: How does the company plan to build the market for intermediate-risk patients? - Management noted that the market is currently underserved, with only 35% receiving adjuvant therapy, and expects this number to grow as data from their studies becomes available [54]

Financial Data and Key Metrics Changes - In Q3, revenues were $329.1 million, down from $335.4 million in the prior year period, reflecting a decrease of approximately 1% [20] - Adjusted operating loss was $24.3 million compared to $20.9 million in the prior year, while adjusted EBITDA was approximately break even compared to $6 million in the prior year [20] - Net loss was $3.5 million compared to a net loss of $1.3 million in the prior year period, with adjusted loss per diluted share increasing to $0.15 from $0.05 [21] Business Line Data and Key Metrics Changes - Children's Book Publishing and Distribution revenues decreased 3% to $197.6 million, with adjusted operating profit improving to $8.9 million from $7.6 million [21] - Book Fairs revenue increased 2% to $113.3 million, driven by higher revenue per fair [22] - Trade Publishing revenues were $69.7 million, down 10% from $77.4 million in the prior year, reflecting timing of major releases [23] - Education segment revenues were $56.1 million, down 2% from $57.2 million, but adjusted operating loss improved to $5.2 million from $6.9 million [25] Market Data and Key Metrics Changes - International segment revenues were $58.7 million, down from $59.3 million a year ago, with a decline attributed to publication timing [26] - Demand for English language learning materials continues to expand globally, representing a long-term opportunity [18] Company Strategy and Development Direction - The company completed sale leaseback transactions generating over $400 million in net proceeds, optimizing the balance sheet and enhancing shareholder value [4][19] - A new $300 million share repurchase authorization was announced, including a $200 million modified Dutch auction tender offer [5][29] - The company aims to return to growth in the education segment by fiscal 2027, focusing on improving product alignment with district needs [16] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed fiscal 2026 adjusted EBITDA guidance of $146 million-$156 million, including a partial year impact from sale-leaseback transactions [31] - The company expects a return to profitability in Q4, driven by improved performance in Book Fairs and Education segments [32] - Management expressed confidence in achieving flat revenue for the full fiscal year, with expectations of 2% growth in Q4 [36][38] Other Important Information - The company established long-term net leverage targets of 2x-2.5x Adjusted EBITDA, balancing balance sheet strength with investment opportunities [28] - Free cash flow in Q3 was $407 million, reflecting proceeds from sale leaseback transactions [27] Q&A Session Summary Question: Confidence in achieving 2% growth in Q4 - Management highlighted Book Fairs as a major factor for revenue growth, with positive initial indications [37][38] Question: Sales pipeline for education solutions - Management noted improvements in the sales pipeline, particularly for summer reading and supplemental materials [42] Question: Adjusted EBITDA guidance and factors influencing it - Management indicated confidence in Q4 profitability due to cost mitigation actions and expected performance in the Entertainment segment [46][48] Question: Performance of the Book Fairs business - Management reported an increase in the number of fairs and revenue per fair, with fewer cancellations compared to the prior year [56] Question: Adjustments to revenue guidance - Management clarified that the adjustment was related to dynamics in the Trade business and not solely the Education segment [60][68]

Financial Data and Key Metrics Changes - In 2025, net sales were approximately $162 million, reflecting a year-over-year decline primarily due to store closures [5][20] - Gross margin improved by 370 basis points to 26.8% for the full year 2025, despite total revenue decline [4][22] - Adjusted EBITDA improved by $8.5 million year-over-year, moving from a loss of $14.5 million to a loss of $6 million [8][22] - GAAP net loss decreased to $24 million for the full year 2025, a $25.5 million improvement compared to a net loss of $49.5 million in 2024 [22] Business Line Data and Key Metrics Changes - Proprietary brand sales penetration increased to 32.8% of cultivation and gardening revenue for the full year 2025, up from 24.2% in 2024 [7][20] - In Q4 2025, proprietary brand sales represented 35.8% of cultivation and gardening revenue, up from 30.4% in the prior year [16] - The storage solutions segment reported net sales of $5.7 million for Q4 2025, up from $4.5 million in Q4 2024, indicating stable demand [17] Market Data and Key Metrics Changes - The company consolidated its retail footprint to 23 locations as of December 31, 2025, with plans to further reduce to approximately 19 locations [5][59] - The company is shifting focus from retail to B2B distribution, indicating a strategic pivot in its market approach [59] Company Strategy and Development Direction - The company aims to reach approximately break-even adjusted EBITDA for the full year 2026, focusing on revenue quality rather than volume [14][24] - Plans to increase proprietary brand sales to 40% of cultivation and gardening revenue by year-end 2026 [9][24] - The company is expanding into new revenue channels and product extensions, particularly in B2B and home gardening markets [10][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's long-term strategy and the potential for sustainable growth in the controlled environment agricultural industry [15][26] - The restructuring efforts have stabilized revenue and improved margins, positioning the company for future profitability [27][28] - Management acknowledged ongoing challenges in the hydroponics market but remains optimistic about the company's ability to adapt and grow [46][52] Other Important Information - The company announced a share repurchase program for up to $10 million of its outstanding common stock, reflecting confidence in its long-term value [14][23] - The company ended 2025 with $46 million in cash and no debt, providing financial flexibility for strategic initiatives [23] Q&A Session Summary Question: Share repurchase program considerations - Management indicated that the decision to repurchase shares was based on the current undervaluation of the stock and the lack of suitable acquisition opportunities [31][32] Question: Sales channels for proprietary brands - Approximately 80% of proprietary brand sales are currently through the company's own channels, with a goal to diversify towards third-party channels [34][35] Question: Outlook for storage solutions segment - Management noted that efforts are being made to consolidate and improve the storage solutions business, which is expected to grow steadily [39][40] Question: Future of retail store closures - The company plans to continue reducing its retail footprint, focusing on B2B operations rather than consumer retail [58][59] Question: Operating expenses and cost reductions - Management expects continued improvements in operating expenses due to prior store closures and ongoing cost reduction initiatives [61]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 reached a record $9.2 million, up 31% year-over-year, bringing full year 2025 revenue to $32 million, a 27% increase over 2024 [14][18] - Prescription device revenue increased 23% year-over-year to $26 million, driven by growth in gammaCore and Quell products [14][18] - Net loss for 2025 was $14 million or $1.65 per share, compared to a net loss of $11.9 million or $1.59 per share in 2024 [21][22] Business Line Data and Key Metrics Changes - VA hospital system remains the largest customer, with 200 facilities purchasing gammaCore products, up from 170 a year ago [14][15] - General wellness revenue reached $5.5 million for the full year, a 97% increase compared to 2024, primarily driven by Truvaga sales [15][16] - Truvaga sales increased by 93% from 2024, totaling $5.4 million [16] Market Data and Key Metrics Changes - Approximately 13,400 VA patients received gammaCore devices, representing roughly 2% penetration of the addressable VA headache market [15] - NHS England remains a key channel for international sales, with ongoing efforts to develop infrastructure for reimbursement in other countries [38] Company Strategy and Development Direction - The company is focused on increasing sales within the VA system and expanding into general wellness with the Truvaga product [8][12] - A leadership transition is underway, with Joshua Lev appointed as Interim President and Michael Fox joining as Chief Operating Officer to enhance commercial efforts [5][8] - The company aims to introduce additional wellness offerings and a next-generation mobile application to support recurring revenue opportunities [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for sustained revenue acceleration and long-term value creation [12][23] - The leadership transition is seen as an opportunity to maintain operational momentum while focusing on growth strategies [6][7] - The company expects 2026 revenue to continue growing at approximately 30% [23] Other Important Information - Gross margin improved to 87% compared to 85% in 2024 [18] - Research and development expenses increased to $2.7 million, primarily for gammaCore Emerald and mobile application development [19] Q&A Session Summary Question: Can you discuss the channels for gammaCore and Quell in 2026? - Management highlighted the growth in the VA channel and the addition of commercial leaders to accelerate growth [30][31] Question: What about the OUS channels and specific geographies? - NHS England remains the primary focus for international revenue, with ongoing efforts to develop reimbursement pathways in other countries [35][38] Question: Will Michael Fox focus on the VA business while Joshua handles wellness? - Michael will oversee broader commercial strategies, including VA and other federal systems, while Joshua will manage wellness products [44][45] Question: Any updates on insurance reimbursement coverage? - The company is focused on Kaiser as a key opportunity for broader reimbursement adoption, with plans to leverage success for additional managed care systems [58][59]

Financial Data and Key Metrics Changes - The company achieved record full-year revenue of $3.9 million, a 20% increase compared to 2024, with fourth quarter revenue of $1.5 million, representing a 92% increase over the prior year period [3][9] - Gross profit for the fourth quarter was $1 million or 69% of revenue, compared to $0.4 million or 46% of revenue in the prior-year quarter, marking a 188% increase and a 23 percentage point improvement in gross margin [10] - Operating expenses totaled $3.9 million for the fourth quarter of 2025, up from $3.5 million in the prior year quarter, while for the full year, operating expenses totaled $15.2 million, compared to $15.5 million in the prior year period [11][12] Business Line Data and Key Metrics Changes - Revenue growth was primarily driven by an increase in surgical procedures across both the Catamaran and SImmetry+ platforms, particularly in the second half of 2025, led by new physician users [3][9] - The company hosted 24 physicians in targeted training sessions for both platforms during the fourth quarter, supporting clinical engagement and adoption [4] Market Data and Key Metrics Changes - The company received FDA 510(k) clearance for the next generation SImmetry+ SI joint fusion system, enhancing its ability to serve a broader range of surgeon preferences and patient anatomies [4][7] - The company expanded its intellectual property portfolio, receiving notices of allowance for multiple applications expected to issue in 2026, bringing its global estate to 29 issued U.S. patents and 31 pending applications [7] Company Strategy and Development Direction - The company is committed to advancing its market position with increased adoption across its expanding portfolio, leveraging regulatory and market momentum to drive broader commercial uptake [8] - The focus is on optimizing the cost structure and scaling operations to extend market reach more efficiently, with plans to accelerate revenue growth and deliver sustained value [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to meet and exceed expectations in 2026, citing strong adoption momentum and an engaged pipeline [22][28] - The company believes that the fourth quarter and full year of 2025 served as a pivotal inflection point, delivering meaningful progress across key priorities [14] Other Important Information - The company ended the quarter with $3.8 million in cash and cash equivalents, compared to $6.5 million as of December 31, 2024, and had no outstanding debt [12] - Subsequent to the quarter end, the company closed a $4.3 million private placement of senior convertible notes to fund commercial expansion and clinical priorities [12][6] Q&A Session Summary Question: What is the outlook for operating expenses in 2026? - Management indicated that the Q4 operating expense rate of $3.9 million is a better baseline moving forward into 2026, with some higher integration costs falling out [16][17] Question: How does the company view revenue growth for 2026? - Management expressed excitement about the adoption momentum and the impact of new product launches, indicating confidence in meeting revenue expectations [21][25] Question: What are the key drivers for revenue growth in 2026? - Management highlighted the multi-product portfolio and the ability to address various patient needs as key drivers for revenue growth, emphasizing commercial expansion and execution [28][27] Question: How is the launch of SImmetry+ impacting access to physicians? - Management noted that the broader portfolio allows for multiple solutions, opening doors to more prospective physicians and medical centers [33][34]

Financial Data and Key Metrics Changes - Curis reported a net income of $19.4 million or $1.23 per share for Q4 2025, compared to a net loss of $9.6 million or $1.25 per share for the same period in 2024, primarily due to a $27.2 million one-time non-cash gain from the sale of Erivedge [10] - For the year ended December 31, 2025, the net loss was $7.6 million or $0.58 per share, a significant improvement from a net loss of $43.4 million or $6.88 per share in 2024 [10] - Research and development expenses decreased to $5.8 million in Q4 2025 from $9 million in Q4 2024, and for the year, they were $28.3 million compared to $38.6 million in 2024 [11] - General and administrative expenses also decreased to $2.9 million in Q4 2025 from $3.4 million in Q4 2024, totaling $14 million for the year compared to $16.8 million in 2024 [11] Business Line Data and Key Metrics Changes - The company is making progress in its Take Aim Lymphoma study for primary CNS lymphoma, with expectations for accelerated submissions to the FDA and EMA [4] - Curis is expanding studies of emavusertib into additional NHL subtypes, particularly focusing on its potential to change the treatment paradigm for CLL patients [5][6] Market Data and Key Metrics Changes - The company is actively enrolling patients in its registrational study for PCNSL, with expectations to complete enrollment within 12-18 months [23] - Initial data from the ongoing AML triplet study showed that five of eight evaluable patients achieved MRD conversion, indicating potential for deeper responses [8][9] Company Strategy and Development Direction - Curis is prioritizing its resources towards NHL studies, particularly PCNSL, while also initiating a proof of concept study in CLL [15] - The company aims to improve treatment outcomes by combining emavusertib with existing therapies to achieve deeper responses and potentially complete remission for patients [6][42] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress in clinical trials and the potential for significant advancements in 2026, particularly in the registrational study for PCNSL and the proof of concept study in CLL [9] - The company anticipates no meaningful revenue in 2026 due to the cessation of cash flows from Erivedge, but believes it has sufficient cash to fund operations into the second half of 2027 [12][29] Other Important Information - Curis has received initial gross proceeds of $20.2 million from financing in January 2026, with expectations for additional proceeds from warrant exercises [12] Q&A Session Summary Question: How is the company prioritizing trial progress between pivotal PCNSL versus CLL and AML? - Management indicated that resources are being prioritized towards NHL, particularly PCNSL, while CLL is in the early stages of study [14][15] Question: Can you provide updates on enrollment for PCNSL? - Management stated that enrollment is on track, with expectations for full enrollment within 12-18 months [23] Question: Should revenue modeling for 2026 reflect no meaningful revenue? - Management confirmed that there will be no meaningful revenue in 2026, as cash flows from Erivedge have ended [29] Question: What kind of data should be expected at ASH 2026 regarding CLL? - Management indicated that they hope to present meaningful data at ASH, focusing on the potential for deeper responses in patients [39][40]

Financial Data and Key Metrics Changes - For fiscal 2025, the company achieved net sales of $1 billion and adjusted EBITDA of $63.6 million, reaching the top end of its guidance [4][22] - In Q4, net sales were $236.2 million, a decline from $275.6 million in the prior year, with a comparable sales decline of 10% [23] - Gross profit for Q4 was $70.9 million, with a gross margin of 30%, down from 33.6% the previous year [23] - SG&A expenses decreased by $11.4 million to $62.4 million, representing 26.4% of net sales [23] Business Line Data and Key Metrics Changes - The company saw strength in dresses, with growth for four consecutive quarters, and a positive turnaround in knit tops during the latter half of Q4 [6][14] - Sub-brands generated over $70 million in sales in 2025, with projected growth of approximately 60% to $110 million in 2026 [11] - The footwear category was successfully reintroduced, with sold-out limited assortments, and is expected to contribute positively in the second half of 2026 [7][15] Market Data and Key Metrics Changes - The company closed 151 stores in fiscal 2025, with an additional 11 closures in Q1 2026, optimizing its store footprint [8][25] - Customer retention rates from closed locations have met or exceeded historical levels, indicating strong brand health [25] Company Strategy and Development Direction - The primary focus for 2026 is to accelerate customer file growth through targeted marketing strategies aimed at acquiring new customers and reactivating lapsed ones [7][19] - The company is implementing a disciplined approach to product development, balancing innovation with reliability, and enhancing its merchandising process [10][14] - The opening price point strategy now represents approximately 30% of total assortment, expected to grow to nearly 40% in stores [16] Management Comments on Operating Environment and Future Outlook - Management acknowledged economic pressures affecting consumer spending, which have been addressed through the opening price point initiative [36] - The company expects to face headwinds in the first half of 2026 due to footwear reintroduction but anticipates positive impacts in the second half [15][47] - The outlook for fiscal 2026 includes expected net sales of $940 million to $960 million and adjusted EBIT of $65 million to $75 million, reflecting margin expansion [27][28] Other Important Information - The company ended Q4 with $200 million in cash and cash equivalents, providing adequate liquidity for its plans [24][25] - Inventory totaled $136.5 million, down 8%, reflecting tighter management and the reduction of the store base [25] Q&A Session Summary Question: Insights on sub-brands performance and growth expectations - Management expressed satisfaction with sub-brands, highlighting strong performers and adjusting growth expectations to mid-teens for the upcoming year [31][32] Question: Reasons for customer lapses and reactivation strategies - Management noted economic pressures as a primary reason for customer lapses and emphasized targeted segmentation and personalized messaging for reactivation [36][37] Question: Sales cadence during the holiday season and tariff impacts - Management reported improvement in sales in January and acknowledged tariff pressures affecting margins, particularly in the footwear category [42][44] Question: Marketing plans for 2026 regarding pricing and loyalty - Management indicated a shift towards less reliance on Torrid Cash redemption and a focus on everyday opening price point opportunities to drive customer engagement [50][51] Question: Strategic outlook for 2026 and pricing promotions - Management confirmed a pivot towards a more offensive strategy, focusing on customer file growth and personalized marketing efforts [62][68]

Eton Pharmaceuticals (NasdaqGM:ETON) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Company ParticipantsDavid Krempa - Chief Business OfficerIpek Erdogan-Trinkaus - Chief Commercial OfficerJames Gruber - CFOSean Brynjelsen - CEOConference Call ParticipantsChase Knickerbocker - Senior Equity Research Analyst of HealthcareMadison El-Saadi - Healthcare Research AnalystRamakanth Swayampakula - Managing Director and Senior Equity research AnalystOperatorGood afternoon, and welcome to the Eton Pharmaceuticals f ...